Aktuellt
SENASTE
FluoGuide announced that the tissues surgically removed using FG001 during the dose-escalation phase of its phase 1/2 trial were, as anticipated, cancerous, confirming that FG001 has positive predictive value. The second part of the trial will give us a clearer view of how big that predictive value is, and the data should be ready by mid-year. Positive but largely expected, so we expect a modestly positive reaction.
LÄS MER
